Apontis Pharma AG
XETRA:APPH
Net Margin
Apontis Pharma AG
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
A
|
Apontis Pharma AG
XETRA:APPH
|
93.7m EUR |
-10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
793.6B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
246.5B CHF |
20%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
235.8B USD |
27%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
180B GBP |
13%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
200.9B CHF |
23%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
166.1B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.9B USD |
13%
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Apontis Pharma AG's most recent financial statements, the company has Net Margin of -10.3%.
You don't have any saved screeners yet